On May 17 news, according to media reports, a research team from the Swiss University of Technology Zurich, the University of Berne, the University of Lausanne and the University of Cork from Ireland has found the "fatal weakness" of the coronavirus, including the new coronavirus.
The report pointed out that the study successfully revealed for the first time the interaction between the viral genome and the ribosome in the "frameshift" process, and found that the virus has "fine control" over the ribosome "frameshift" process, which is expected to facilitate the interference of the "frameshift" process. And the development of drugs that inhibit virus replication.
This study shows that a molecule called merafloxacin is a compound that better inhibits the "frameshift" process. It can reduce the titer of the new coronavirus by 3-4 orders of magnitude and is not toxic to cells.
Experts pointed out that the development of specific antiviral drugs must first be based on the screening and design of drug targets based on the key mechanisms of the new coronavirus invading human cells, self-replication, and pathogenicity.
There is no shortcut to new drug research and development. The development of a brand-new drug may require long-term investment until it is finally approved. There are specific scientific laws and rigorous logic behind the research and development of new coronavirus drugs, which cannot be achieved overnight.